Welcome to LinkedIn Novartis in Slovenia! We are glad to see you!

We would like to share with you our guidelines for using Novartis' LinkedIn. We kindly ask you to follow them to ensure the best experience for our company followers. We are looking forward to communicating with you.

Novartis in Slovenia would like to provide improved information, updates, and news to its stakeholders, while following and responding to communication about Novartis in Slovenia on LinkedIn.

We are excited to communicate with you using @comments and replies; however, we would like to remind you that we work in a heavily regulated industry with a unique legal position and code of conduct. Therefore, we cannot engage in sensitive topics, such as discussions about products – ours or other companies’– or treatment options on this page. These discussions are best held privately with your healthcare professional. We reserve the right to remove content or posts not related to the relevant topic or posts containing violence, discrimination, or harassment. Content uploaded by anyone other than Novartis d.o.o and Slovenian subsidiary Novartis Pharma Services Inc. (hereinafter referred to as: Novartis in Slovenia), is not approved.

Due to these regulations, we need to ensure discussions occurring on our LinkedIn page stay on topic and are constructive. Comments that include any of the following items are not constructive to the dialogue and may be deleted from the Novartis in Slovenia page:

  • If your posts are product related
  • If your posts include profanity, defamatory, libelous, offensive, abusive, discriminatory or demeaning content (including images, videos and links);
  • If your posts are disparaging, threatening, condone violence or illegal behavior;
  • If your posts are off-topic;
  • If your posts offer health or medical advice;
  • If your posts contain any personal information e.g. names of individuals, email address or phone number;
  • If your posts violate another’s copyright or intellectual property;
  • If your posts are commercial, e.g. sells products and services, or recruit fans and
    followers;
  • If your posts are excessively repetitive and/or disruptive to the community or are spam;
  • If your posts contain proprietary, confidential, sensitive, or nonpublic information;
  • If your posts don’t follow LinkedIn’s User Agreement

We kindly ask you to respect the members of our community.

Please be aware that members who continuously and repeatedly contravene the above rules may be blocked from our LinkedIn page. In this case the user will no longer be able to follow our news or comment on our posts or send messages. 

The languages of this community are Slovene and English.

Although Novartis in Slovenia is and will undertake all steps to make sure that the information on these pages is truly accurate and up-to-date, it cannot guarantee their accuracy and completeness and does not assume any responsibility. Novartis in Slovenia also reserves the right to change the content of these pages in any way at any time, regardless of the reason and without prior notice. Any content made available on this website are provided to users at their own risk.

NEITHER NOVARTIS NOR ANY OTHER LEGAL OR NATURAL PERSON WHO PARTICIPATED IN THE DEVELOPMENT AND CREATION OF THESE SITES WILL IN NO EVENT ASSUME NO LIABILITY OR RESPONSIBILITY FOR ANY DAMAGES THAT ARISING AS A RESULT OR RELATED TO THE EXISTENCE, ACCESS AND/OR USE OF THESE PAGES AND/OR INFORMATION CONTAINED IN THESE PAGES, AND/OR DUE TO THE UNENFORCEABILITY OF USING THE INFORMATION ON THESE PAGES AND/OR ANY ERROR OR OMISSIONS IN THE CONTENT CONTAINED ON THIS SITE REGARDLESS OF WHETHER THEY WERE NOTIFIED ON POSSIBILITY OF SUCH DAMAGE.

This site features brands and services displayed in a different typology, using a symbol, trademark, or mark, including the Novartis logo. These are registered trademarks owned or licensed by Novartis or its affiliates. Any unauthorized use (as defined in the text) or abuse of these trademarks is expressly prohibited.

Adverse events and adverse drug reactions

If you notice any adverse events or reactions when taking Novartis medicine, send us an e-mail to [email protected] and consult with your physician, pharmacist or other healthcare professional.

We suggest sharing as little personal information as possible on the LinkedIn profile especially sharing any specific data concerning your personal health should be avoided. Should you, however, decide to include a post detailing any adverse events, Novartis may need to contact you to find out more information. Posts of this nature may need to be removed from our LinkedIn page; this is due to legal obligations concerning drug safety reporting.

Storing and using private information

Content you share in this channel is available to the public. Novartis in Slovenia may process, store and use information you chose to share through this channel for reasons such as improving its products and services, reporting adverse events, or providing you with assistance upon your request. To facilitate requests, we may ask for additional information which will only be used for the purpose it was initially collected.

In case of an adverse event or product issue you report to us (adverse events related emails send to [email protected], product issue related emails address to [email protected]), we will need to store and use identifying information you provide, e.g. your name, health data etc., in accordance with the applicable laws. This information is required to be submitted to the Novartis in Slovenia Drug Safety department and/or regulatory authorities. In such case, we are required to store your personal data inline with the Pharmacovigilance Privacy Notice. To manage your comments and messages, service providers acting on behalf of Novartis can also be hired, i.e. they also have access to the personal information you share with us. Such service providers are contractually obliged to protect the confidentiality and security of your personal data, in compliance with applicable law.

Please note that LinkedIn also has access to information you share with us through their
platform. For more details read the LinkedIn Privacy Policy.

If you ask questions in the comments that are not general and more information is required to provide you with an answer, we will ask you to send the question to [email protected]. We will answer your question privately and as soon as possible.

We will do our best to respond to any direct messages within 48 hours. The LinkedIn accounts that Novartis in Slovenia follows or is followed by are not an indication of Novartis in Slovenia’s endorsement of these accounts or the content they produce. Any content that Novartis in Slovenia shares or reacts to is not an endorsement of the content itself, nor the producer of the content.

If you contact Novartis in Slovenia, for example by sending a message to this account, information about you (personal data) may be collected and transferred to Novartis in Slovenia systems, but only where this is necessary for the purposes described below. In such cases, and limited to such cases, Novartis in Slovenia is responsible for the processing of your personal data as it decides why and how it is processed, acting as a controller.

Data we collect

As necessary for the purposes described below, we may collect personal data, including:

  • your general profile contact data (e.g. username);
  • personal data contained in your posts or comments to this account; and
  • personal data contained in messages sent to us or posted comments.

For which purposes do we use your personal information and why is this justified?

We will not process your personal information if we do not have a proper justification foreseen in the law for that purpose. Therefore, we will only process your personal information if:

  • the processing is necessary to comply with our legal or regulatory obligations;
  • the processing is necessary to protect your interests or other people’s interests; 
  • the processing is necessary for our legitimate interests and does not unduly affect your interests or fundamental rights and freedoms. Please note that, when processing your personal information on this last basis, we always seek to maintain a balance between our legitimate interests and your privacy. Examples of such ‘legitimate interests’ are data processing activities performed are explained below.

Personal data may be used by us for the following purposes:

  • to manage and answer any questions, requests, or complaints you raise;
  • to inform our communications activities, including the content and target audience of the posts from our social media accounts; and
  • we ask you not to do so, but if you use LinkedIn to alert us to medicinal side effects, product quality complaints or other regulated situations, we may log your query and contact you for additional information. We may also be required to disclose your personal data to regulatory authorities. For more information about this, please refer to our Pharmacovigilance Privacy Notice

In addition, we may also process your personal data for the following general purposes:

  • improving the quality of our products and services;
  • providing you with adequate and updated information about diseases;
  • organize patient support or assistance programs (including connecting you with health resources and patients associations upon your request);
  • managing our IT resources, including infrastructure management and business continuity;
  • preserving Novartis’ economic interests and ensure compliance and reporting (such as complying with our policies and local legal requirements, tax and deductions, managing alleged cases of misconduct or fraud, conducting audits and defending litigation);
  • managing mergers and acquisitions involving our company;
  • archiving and record-keeping; 
  • any other purposes imposed by law and authorities.

Who has access to your personal data and to whom are they transferred?

We will not sell, share, or otherwise transfer your personal data to third parties other than those indicated in this Privacy Notice.

In the course of our activities and for the same purposes as those listed in this Privacy Notice, your personal data can be accessed by, or transferred to (if necessary):

  • our personnel (including personnel, departments or other companies of the Novartis group of which Novartis in Slovenia is a member); 
  • our other suppliers and services providers that provide services and products to us;
  • our IT systems providers, cloud service providers, database providers and consultants
  • any third party to whom we assign or novate any of our rights or obligations, and; 
  • our advisors and external lawyers in the context of the sale or transfer of any part of our business or its assets 

The above third parties are contractually obliged to protect the confidentiality and security of your personal data, in compliance with applicable law. Your personal data can also be accessed by or transferred to any national and/or international regulatory, enforcement, public body or court where we are required to do so by applicable law or regulation or at their request.

The personal data we collect from you may also be processed, accessed or stored in a country outside Slovenia or the country where you are located, which may not offer the same level of protection of personal data.

If we transfer your personal data to external companies in other jurisdictions, we will make sure to protect your personal data by applying the level of protection required under the local data protection/privacy laws applicable to Novartis. For intra-group transfers of personal data, the Novartis Group has adopted Binding Corporate Rules - a system of principles, rules and tools, provided by European law, in an effort to ensure effective levels of data protection relating to transfers of personal data outside the EEA and Switzerland. Read more about the Novartis Binding Corporate Rules here.

We will handle personal data, including those sent to the listed e-mail addresses, very carefully and treat them only in order to answer your question as accurately as possible or to meet legal requirements.

How long do we store your personal data?

Your personal data will be kept for as long as it is necessary to fulfill the purpose for which it was collected, or to meet legal or regulatory requirements, and for no more than five years. Pharmacovigilance information will be kept according to pharmacovigilance legislation (Find out more information in the Pharmacovigilance Privacy Notice).

What are your rights and how can you exercise them?

Subject to conditions provided by law, you have the right to: 

  • access your personal data as processed by us and, if you believe that any information relating to you is incorrect, obsolete or incomplete, to request its correction or updating; 
  • request erasure of your personal data or restriction to certain category processing;
  • withdraw your consent at any time, without prejudice to the lawfulness of our processing of your personal data prior to such withdrawal;
  • object, in whole or in part, to the processing of your personal data;
  • request data portability, the personal data you provided to us is returned to you or transferred to a person of your choice in a structured, frequently used and machine-readable format without any obstacles on our part and subject to your obligation of confidentiality.

Please note that LinkedIn also has access to information you share with us through their
platform. For more details read the LinkedIn Privacy Policy.

Thank you for your attention and for being a part of our community.

Further Information

Novartis in Slovenia will not be responsible for use of your comments outside of these intended purposes by you or any third party. No part of our responses to you may be published and should not be disseminated to third parties out of context of the original enquiry.

Date: October 4, 2023

The content provided on this website is for general informational and educational purposes only and is in no way intended as a substitute for medical or pharmaceutical consultation. Accordingly, before taking any actions based upon such information, we encourage you to consult your doctor or other healthcare professional.